| Sep 27 |
SAGE, BIIB End Collaboration for Neurology Candidate SAGE-324
|
| Sep 27 |
SAGE Therapeutics’ SAGE-324 Collaboration with Biogen Ends
|
| Sep 26 |
Biogen Terminates Collaboration With Sage Therapeutics For Neurological Disorder Candidate
|
| Sep 26 |
Biogen to end Sage deal for neuro candidate
|
| Sep 26 |
Sage Therapeutics Announces Discontinuation of the Collaboration with Biogen on the SAGE-324 Program
|
| Sep 25 |
Sage Therapeutics, Inc. (SAGE) Hits 52-Week Lows After Trial Failures, According to Short Sellers
|
| Sep 17 |
Sage Therapeutics files prospectus to offer $250M of common stock
|
| Aug 30 |
Sage Therapeutics (SAGE) Down 17.1% Since Last Earnings Report: Can It Rebound?
|
| Aug 3 |
Analysts Have Been Trimming Their Sage Therapeutics, Inc. (NASDAQ:SAGE) Price Target After Its Latest Report
|
| Aug 2 |
Sage Therapeutics Second Quarter 2024 Earnings: Misses Expectations
|
